SCHEMBL956142

SCHEMBL956142

CC(=O)/C=C/C1=C(C)C(OC(C)=O)CCC1(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.43
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CYP26A1 O43174 5/20 0.39
RARA P10276 6/20 0.39
CYP1A2 P05177 1/20 0.36
HIF1A Q16665 2/20 0.36
GMNN O75496 2/20 0.36
PMP22 Q01453 2/20 0.36
TSHR P16473 1/20 0.36
LMNA P02545 1/20 0.36
APEX1 P27695 1/20 0.36
CYP3A4 P08684 2/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SLCO1B3 Q9NPD5 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
SLCO1B1 Q9Y6L6 1/20 0.33
RARB P10826 4/20 0.32
RARG P13631 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL956143 1.00 MAPT (0.43) MAPTALDH1A1SMN1; SMN2CYP26A1RARA
SCHEMBL11454726 0.84 ALDH1A1 (0.35) MAPTALDH1A1SMN1; SMN2CYP26A1TSHR
SCHEMBL8011545 0.80 MAPT (0.61) MAPTALDH1A1SMN1; SMN2CYP26A1RARA
SCHEMBL8011547 0.80 MAPT (0.61) MAPTALDH1A1SMN1; SMN2CYP26A1RARA
SCHEMBL11333459 0.80 MAPT (0.40) MAPTALDH1A1SMN1; SMN2CYP26A1RARA
SCHEMBL11333475 0.80 MAPT (0.40) MAPTALDH1A1SMN1; SMN2CYP26A1RARA
SCHEMBL4389193 0.80 ALDH1A1 (0.74) MAPTALDH1A1SMN1; SMN2CYP26A1RARA
SCHEMBL5077672 0.80 ALDH1A1 (0.74) MAPTALDH1A1SMN1; SMN2CYP26A1RARA
SCHEMBL14049811 0.79 MAPT (0.47) MAPTALDH1A1SMN1; SMN2CYP26A1RARA
SCHEMBL13589857 0.76 MAPT (0.56) MAPTALDH1A1SMN1; SMN2CYP26A1RARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3100723-B1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE BIKAM PHARMACEUTICALS INC (US) 2019-06-12 EP disclosed
US-20170037018-A1 Opsin-Binding Ligands, Compositions and Methods of Use BIKAM PHARMACEUTICALS INC. (US) 2017-02-09 US disclosed
US-9562022-B2 Opsin-binding ligands, compositions and methods of use BIKAM PHARMACEUTICALS, INC. (US) 2017-02-07 US disclosed
EP-3100723-A1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE Bikam Pharmaceuticals, Inc. (US) 2016-12-07 EP disclosed
EP-2442644-B1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE BIKAM PHARMACEUTICALS INC (US) 2016-08-10 EP disclosed
EP-2442644-A1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE Bikam Pharmaceuticals, Inc. (US) 2012-04-25 EP disclosed
US-20110003784-A1 Opsin-binding ligands, compositions and methods of use BIKAM PHARMACEUTICALS INC. 2011-01-06 US disclosed
WO-2010147653-A1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE BIKAM PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037018-A1 Opsin-Binding Ligands, Compositions and Methods of Use CRYAB, CRYAA, UACA MAPT 741/4885ALDH1A1 2958/4885SMN1; SMN2 2172/4885
US-20110003784-A1 Opsin-binding ligands, compositions and methods of use CRYAB, CRYAA, UACA MAPT 741/4885ALDH1A1 2958/4885SMN1; SMN2 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.